Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 7
2006 1
2012 2
2013 5
2014 4
2015 4
2016 4
2017 4
2018 6
2019 28
2020 60
2021 95
2022 85
2023 121
2024 78

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Results by year

Filters applied: . Clear all
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21. …
The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was gre …
Bempedoic Acid.
[No authors listed] [No authors listed] 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33104321 Free Books & Documents. Review.
No relevant published information exists on the use of bempedoic acid during breastfeeding. Bempedoic acid and its metabolites are 99% plasma protein bound, so amounts in milk are likely very low. However, because of a concern with disruption of infant …
No relevant published information exists on the use of bempedoic acid during breastfeeding. Bempedoic acid and i …
Bempedoic Acid: for Whom and When.
Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Ruscica M, et al. Curr Atheroscler Rep. 2022 Oct;24(10):791-801. doi: 10.1007/s11883-022-01054-2. Epub 2022 Jul 28. Curr Atheroscler Rep. 2022. PMID: 35900636 Free PMC article. Review.
The remit of this review is to give clinical insights on the safety and efficacy of bempedoic acid and to understand for whom it should be prescribed. ...Bempedoic acid does not lead to the risk of new-onset diabetes, and moderately improves the glycae …
The remit of this review is to give clinical insights on the safety and efficacy of bempedoic acid and to understand for whom …
Bempedoic Acid.
[No authors listed] [No authors listed] 2023 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Jul 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37487014 Free Books & Documents. Review.
Bempedoic acid is a small molecule inhibitor of adenosine triphosphate-citrate lyase that is used as a cholesterol lowering agent in patients with hypercholesterolemia and high risk or with known atherosclerotic cardiovascular disease who fail to have an adequate re
Bempedoic acid is a small molecule inhibitor of adenosine triphosphate-citrate lyase that is used as a cholesterol lowering ag
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Nissen SE, et al. JAMA. 2023 Jul 11;330(2):131-140. doi: 10.1001/jama.2023.9696. JAMA. 2023. PMID: 37354546 Free PMC article.
OBJECTIVE: To determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients. ...CONCLUSIONS: In a subgroup of high-risk primary prevention patients, bempedoic acid treatment was associated with reduced major cardiova …
OBJECTIVE: To determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients. ...CONCLUSION …
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK. Tummala R, et al. Ann Med. 2022 Dec;54(1):1287-1296. doi: 10.1080/07853890.2022.2059559. Ann Med. 2022. PMID: 35533049 Free PMC article. Review.
Bempedoic acid also reduced inflammatory markers like hs-CRP. Given these results, bempedoic acid alone and in combination with ezetimibe received the USA FDA approval for adults with heterozygous familial hypercholesterolaemia or established atheroscl
Bempedoic acid also reduced inflammatory markers like hs-CRP. Given these results, bempedoic acid alone and in c
Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Ballantyne CM, et al. Cardiovasc Drugs Ther. 2021 Aug;35(4):853-864. doi: 10.1007/s10557-021-07147-5. Epub 2021 Apr 5. Cardiovasc Drugs Ther. 2021. PMID: 33818688 Free PMC article. Review.
Bempedoic acid is generally well tolerated with no clinically meaningful increase in muscle-related symptoms relative to placebo, even in patients taking maximally tolerated statins. ...The potential for a reduced incidence of major cardiovascular events with bem
Bempedoic acid is generally well tolerated with no clinically meaningful increase in muscle-related symptoms relative to place
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Ray KK, et al. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917. N Engl J Med. 2019. PMID: 30865796 Free article. Clinical Trial.
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term s …
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-densit …
Bempedoic Acid: First Approval.
Markham A. Markham A. Drugs. 2020 May;80(7):747-753. doi: 10.1007/s40265-020-01308-w. Drugs. 2020. PMID: 32314225 Review.
Bempedoic acid is a non-statin antihyperlipidaemic drug being developed by Esperion Therapeutics for the treatment of hypercholesterolaemia. ...This article summarizes the milestones in the development of bempedoic acid leading to these first approvals
Bempedoic acid is a non-statin antihyperlipidaemic drug being developed by Esperion Therapeutics for the treatment of hypercho
Bempedoic acid for the treatment of dyslipidemia.
Marrs JC, Anderson SL. Marrs JC, et al. Drugs Context. 2020 Aug 24;9:2020-6-5. doi: 10.7573/dic.2020-6-5. eCollection 2020. Drugs Context. 2020. PMID: 32922503 Free PMC article. Review.
Bempedoic acid has been demonstrated to lower LDL-C levels by 15-25% in clinical trials and up to 38% when combined with ezetimibe. ...This outcomes trial will be pivotal for determining the role of bempedoic acid in the non-statin lipid-lowering armam
Bempedoic acid has been demonstrated to lower LDL-C levels by 15-25% in clinical trials and up to 38% when combined with ezeti
445 results